Literature DB >> 32969947

Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome.

Bryson W Katona1, Jacquelyn Powers2, Danielle B McKenna2, Jessica M Long2, Anh N Le2, Ryan Hausler2, Kristin Zelley3, Sarah Jennings3, Susan M Domchek2, Katherine L Nathanson4,5, Suzanne P MacFarland3, Kara N Maxwell2,5.   

Abstract

INTRODUCTION: To assess the upper gastrointestinal (UGI) cancer risk and surveillance outcomes in Li-Fraumeni syndrome (LFS).
METHODS: Analysis of the International Agency for Research on Cancer database and a single-center adult LFS cohort.
RESULTS: UGI cancer was present in 7.2% of families and 3.9% of individuals with a pathogenic/likely pathogenic TP53 mutation in International Agency for Research on Cancer; 29% occurred before age 30. Our institutional cohort had 35 individuals (31% of the LFS cohort) with 48 cumulative upper endoscopies; 3 (8.5%) individuals had concerning UGI findings. DISCUSSION: UGI cancer is observed in LFS. Upper endoscopy should be part of a comprehensive LFS surveillance program.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32969947      PMCID: PMC8263231          DOI: 10.14309/ajg.0000000000000935

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  14 in total

1.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR.

Authors:  Hui Yang; Kai Wang
Journal:  Nat Protoc       Date:  2015-09-17       Impact factor: 13.491

Review 2.  Surveillance recommendations for patients with germline TP53 mutations.

Authors:  Mandy L Ballinger; Gillian Mitchell; David M Thomas
Journal:  Curr Opin Oncol       Date:  2015-07       Impact factor: 3.645

3.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019.

Authors:  Samir Gupta; Dawn Provenzale; Xavier Llor; Amy L Halverson; William Grady; Daniel C Chung; Sigurdis Haraldsdottir; Arnold J Markowitz; Thomas P Slavin; Heather Hampel; Reid M Ness; Jennifer M Weiss; Dennis J Ahnen; Lee-May Chen; Gregory Cooper; Dayna S Early; Francis M Giardiello; Michael J Hall; Stanley R Hamilton; Priyanka Kanth; Jason B Klapman; Audrey J Lazenby; Patrick M Lynch; Robert J Mayer; June Mikkelson; Shajan Peter; Scott E Regenbogen; Mary A Dwyer; Ndiya Ogba
Journal:  J Natl Compr Canc Netw       Date:  2019-09-01       Impact factor: 11.908

4.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.

Authors:  Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin
Journal:  Lancet Oncol       Date:  2011-05-19       Impact factor: 41.316

5.  Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome.

Authors:  Patricia Wong; Sigitas J Verselis; Judy E Garber; Katherine Schneider; Lisa DiGianni; David H Stockwell; Frederick P Li; Sapna Syngal
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

6.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Authors:  Gaëlle Bougeard; Mariette Renaux-Petel; Jean-Michel Flaman; Camille Charbonnier; Pierre Fermey; Muriel Belotti; Marion Gauthier-Villars; Dominique Stoppa-Lyonnet; Emilie Consolino; Laurence Brugières; Olivier Caron; Patrick R Benusiglio; Brigitte Bressac-de Paillerets; Valérie Bonadona; Catherine Bonaïti-Pellié; Julie Tinat; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

Review 7.  Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.

Authors:  Amina Amadou; Maria I W Achatz; Pierre Hainaut
Journal:  Curr Opin Oncol       Date:  2018-01       Impact factor: 3.645

8.  Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome.

Authors:  Suzanne P MacFarland; Kristin Zelley; Jessica M Long; Danielle McKenna; Petar Mamula; Susan M Domchek; Katherine L Nathanson; Garrett M Brodeur; Anil K Rustgi; Bryson W Katona; Kara N Maxwell
Journal:  Gastroenterology       Date:  2018-09-19       Impact factor: 22.682

Review 9.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

10.  Gastric cancer in individuals with Li-Fraumeni syndrome.

Authors:  Serena Masciari; Akriti Dewanwala; Elena M Stoffel; Gregory Y Lauwers; Hui Zheng; Maria Isabel Achatz; Douglas Riegert-Johnson; Lenka Foretova; Edaise M Silva; Lisa Digianni; Sigitas J Verselis; Katherine Schneider; Frederick P Li; Joseph Fraumeni; Judy E Garber; Sapna Syngal
Journal:  Genet Med       Date:  2011-07       Impact factor: 8.822

View more
  3 in total

1.  Contributions of NFKB1 -94insertion/deletion ATTG polymorphism to the susceptibility of gastrointestinal cancers: A meta-analysis.

Authors:  Hanqiang Wu; Jianrong Liang
Journal:  J Cell Mol Med       Date:  2021-10-21       Impact factor: 5.310

Review 2.  Endoscopic Surveillance in Patients with the Highest Risk of Gastric Cancer: Challenges and Solutions.

Authors:  Jessica M Long; Jessica Ebrahimzadeh; Peter P Stanich; Bryson W Katona
Journal:  Cancer Manag Res       Date:  2022-10-10       Impact factor: 3.602

Review 3.  Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer.

Authors:  Darina Kohoutova; Matthew Banks; Jan Bures
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.